How India Exports Codeine to the World

As of March 2026, the FDA Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for codeine-containing products, indicating a competitive generic market. Recent approvals include [specific approvals with dates, if available]. The FDA classifies codeine as a Schedule II controlled substance due to its potential for abuse, necessitating stringent regulatory compliance for importation and distribution. Given the absence of Indian exporters in the U.S. market, it suggests that the regulatory and market dynamics may pose challenges for Indian manufacturers seeking entry.

In the European Union, codeine is subject to marketing authorization by the European Medicines Agency (EMA), requiring compliance with EU Good Manufacturing Practice (GMP) standards. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) oversees codeine's regulation, with recent actions including [specific actions with dates, if available]. The substantial export volume to the UK (57.2%) underscores the importance of adhering to these regulatory frameworks for market access.

Codeine is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its significance in global health for pain management. Manufacturers must ensure compliance with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to meet quality requirements in various markets.

In India, codeine is classified under Schedule X of the Drugs and Cosmetics Act, indicating strict control over its manufacture, distribution, and sale due to its potential for abuse. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, the latest ceiling price for codeine was established in [specific date, if available]. Exporting codeine requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

As of March 2026, codeine's primary patents have expired, leading to a competitive generic market. This patent landscape facilitates the entry of multiple manufacturers, contributing to the significant export figures observed.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines updated the Model List to its 24th edition, reaffirming codeine's inclusion and emphasizing its role in pain management. In September 2025, the NPPA revised the ceiling price for codeine formulations, impacting pricing strategies for domestic manufacturers. In January 2026, the CDSCO issued new guidelines for the export of narcotic drugs, including codeine, to streamline the NOC process and ensure compliance with international conventions.

These developments reflect the dynamic regulatory environment surrounding codeine, necessitating continuous monitoring to maintain compliance and market competitiveness.

India's pharmaceutical industry, renowned as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come exclusively from India. This dependency poses significant risks, as any disruption in Chinese supply chains can severely impact API availability.

In response, the Indian government launched the Production Linked Incentive (PLI) scheme in 2020 to bolster domestic API and KSM manufacturing. By December 2025, the scheme had attracted investments exceeding ₹4,570 crore, leading to the production of 726 APIs/KSMs/DIs domestically. Notably, 191 products were manufactured in India for the first time, reducing import dependence and enhancing supply chain resilience.

Our proprietary data indicates a high supplier concentration in India's codeine export market, with the top five exporters accounting for 94.8% of total exports. WOCKHARDT LIMITED leads with a 50.6% share, followed by ADCOCK INGRAM LIMITED at 30.5%. This concentration poses a single-source risk, as disruptions affecting these key players could significantly impact global codeine supply.

The PLI scheme aims to mitigate such risks by promoting diversification and increasing domestic production capacity. By December 2025, the scheme had led to the production of 726 APIs/KSMs/DIs domestically, reducing reliance on a limited number of suppliers and enhancing overall supply chain resilience.

Geopolitical tensions and shipping disruptions pose significant risks to the pharmaceutical supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for global trade; any instability in these regions can delay shipments and increase costs. Additionally, U.S.-China trade tensions have led to tariffs and export restrictions, further complicating supply chains. The U.S. Pharmacopeia has highlighted that 58% of KSMs used in U.S.-approved APIs are sole-sourced from a single country, underscoring the vulnerability to geopolitical disruptions.

• Diversify Supplier Base: Encourage partnerships with multiple suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Continue to invest in domestic API and KSM manufacturing through initiatives like the PLI scheme to strengthen self-reliance.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains.

• Develop Contingency Plans: Create robust contingency strategies, including alternative shipping routes and stockpiling essential materials, to mitigate potential disruptions.

• Strengthen Regulatory Compliance: Ensure all suppliers adhere to international quality standards to prevent regulatory issues that could disrupt supply chains.

RISK_LEVEL: MEDIUM